BioE3 Policy Latest News
- India remains heavily dependent on imports for active pharmaceutical ingredients (APIs), fermentation-based drugs, enzymes for biofuels, and biofertilizer reagents.
- Post Covid-19 pandemic, the government has accelerated efforts for domestic manufacturing under policies like the PLI scheme.
- The Biotechnology for Economy, Environment, and Employment (BioE3) policy/ BioE3 policy of the Government of India envisions setting up 16 biomanufacturing hubs to strengthen the bioeconomy and ensure self-reliance (Atmanirbharta).
India’s Bioeconomy
- The bioeconomy is an economic system that utilizes renewable biological resources from plants, animals, and microorganisms—along with organic waste—to create food, feed, energy, and bio-based products.
- As in December 2023, Bioeconomy contributes 4.25% to India’s Gross Domestic Product (GDP).
- Indian Bioeconomy has grown from $10 billion in 2014 to $151 billion in 2023, achieving this target two years ahead of projections for 2025.
- The number of Biotech Startups has grown from 50 Biotech Startups in 2014 to 8,531 Biotech Startups in 2023.
About the BioE3 Policy
- Launched on August 27, 2024, it is a Union S&T Ministry’s policy that sets forth a framework to ensure the adoption of cutting-edge advanced technologies for promoting Biomanufacturing.
- The policy outlines guidelines and principles for enabling mechanisms for ‘Fostering High Performance Biomanufacturing’ in the country across diverse sectors.
- It is aligned with India’s vision of Green Growth and also with the Lifestyle for Environment (LiFE) initiative that envisions collective approach towards sustainability.
Key Features of the BioE3 Policy
- Biomanufacturing hubs:
- Around 16 hubs to be set up across India.
- Each hub will house large fermenters (500–1,000 litres).
- Focus: Fermentation-based medicines, biofuels, bioproteins, carbon capture technologies, and novel monoclonal antibody treatments.
- Hubs will pool resources → reducing capital burden for start-ups and MSMEs.
- Product focus:
- The government has listed approximately 1,000 critical products needed for indigenous manufacturing.
- Categories:
- APIs and drugs
- Enzymes for biofuels
- Reagents for biofertilizers
- Smart proteins and nutrition enhancers
- Carbon capture innovations
Biofoundries - The First Step
- 6 Biofoundries already supported by Department of Biotechnology (DBT):
- NABI, Mohali, for sustainable food & nutrition.
- Tata Memorial Centre, for new drugs.
- ICGEB, New Delhi, for synthetic biology, microbial cells, biofuels, carbon capture.
- THSTI, Faridabad, for monoclonal antibody therapies.
- IPFT, Gurugram, for biopesticides.
- NCCS, Pune, for enzymes and metabolites.
- Function: Conduct proof-of-concept testing, and innovations are transferred to hubs for scaling up.
Implementation Model
- Location: The biomanufacturing hubs will be set up within research institutes, private companies, or near knowledge hubs.
- Accessibility: Open to government R&D labs, universities, start-ups, and private industry.
- Cost-sharing model: The start-ups will be charged a maximum of 5% over the actual costs while private companies may be charged up to 15% over the cost.
- IPR policy: Facilities will not claim IP rights, ensuring innovation ownership with developers.
Significance of BioE3 Policy for India
- Reduces import dependency in critical pharma and bio-based sectors.
- Strengthens bioeconomy and aligns with Atmanirbhar Bharat vision.
- Supports innovation-to-market pipeline through biofoundries → hubs.
- Boosts R&D collaboration among government, academia, and industry.
- Promotes start-up ecosystem in biotechnology.
Conclusion
- The BioE3 policy, by integrating biofoundries with biomanufacturing hubs, positions India to emerge as a global leader in biotechnology-driven solutions for health, energy, and agriculture.
- Going forward, sustained investment, industry-academia collaboration, and supportive regulatory frameworks will be key to realising the vision of a self-reliant and innovation-led bioeconomy.
Source: IE
BioE3 Policy FAQs
Q1: Why has the Government of India launched the BioE3 policy?
Ans: The policy aims to reduce India’s import dependency in pharmaceuticals, biofuels, and bio-based products by setting up 16 biomanufacturing hubs.
Q2: How will biomanufacturing hubs under the BioE3 policy support start-ups and MSMEs in India?
Ans: These hubs pool resources by providing shared large fermenters and facilities, reducing the need for heavy capital investment.
Q3: What role do biofoundries play in India’s bioeconomy?
Ans: Biofoundries act as specialised facilities for proof-of-concept testing in areas like new drugs, biofuels, and monoclonal antibodies.
Q4: What is the significance of the cost-sharing and IPR model adopted in the BioE3 policy?
Ans: It allows start-ups and companies to access facilities at subsidised costs while retaining full intellectual property rights, thus encouraging innovation.
Q5: In what ways can the BioE3 policy contribute to India’s Atmanirbhar Bharat vision?
Ans: By promoting domestic manufacturing of bio-products, supporting innovation-to-market pipelines, and strengthening the biotechnology ecosystem.